TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28884308
Drug: Usual pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual pharmacological therapy plus 2-week spa therapy
Study: 28884308
Drug: Usual pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual pharmacological therapy alone
Study: 24019259
Drug: KB001 3
Normalized name: KB001
DrugBank: KB001 (DB05222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KB001 3 mg/kg
Study: 24019259
Drug: KB001 10
Normalized name: KB001
DrugBank: KB001 (DB05222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KB001 10 mg/kg
Study: 20160047
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg lersivirine plus 20 ml Maalox Max
Study: 20160047
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg lersivirine alone
Study: 18553042
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1,000 mg)
Study: 12847386
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg in isotonic saline)
Study: 16021874
Drug: alternating treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: alternating treatment (stavudine/didanosine for 12 weeks followed by zidovudine/lamivudine)
Study: 2064702
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 ml saline solution NaCl 0.9%)
Study: 20558907
Drug: Sonazoid (ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonazoid (ultrasound contrast agent)
Study: 12838194
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose regimen (10,000 IU 3 times per week)
Study: 7743787
Drug: Stepped-care regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care regimen (initial treatment with niacin followed by other agents if needed)
Study: 7743787
Drug: Lovastatin (HMG-CoA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (HMG-CoA reductase inhibitor)
Study: 2289390
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg rectal suppository one hour pre-operatively)
Study: 28673219
Drug: 1,200 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 ml carbohydrate solution leading up to admission (up until two hours pre-colonoscopy)
Study: 21477333
Drug: Glandosane (G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glandosane (G)
Study: 21477333
Drug: Both saliva
Normalized name: Dunaliella salina extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both saliva substitutes (SN and G)
Study: 15599323
Drug: Daclizumab 1
Normalized name: daclizumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 1 mg/kg on day 0 and every 14 days for five doses (group 1, n = 30)
Study: 15599323
Drug: Daclizumab 2
Normalized name: daclizumab 25 MG per 5 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 2 mg/kg on day 0 and on the day of discharge (group 2, n = 22)
Study: 15599323
Drug: Daclizumab 1
Normalized name: daclizumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 1 mg/kg (group 1)
Study: 15599323
Drug: Daclizumab 2
Normalized name: daclizumab 25 MG per 5 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 2 mg/kg (group 2)
Study: 9165608
Drug: Desmopressin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin treatment (both intravenous and oral)
Study: 29363373
Drug: Short-course low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Short-course low-dose oral prednisolone (tapering doses over 2 weeks)
Study: 29363373
Drug: Short-course low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Short-course low-dose oral prednisolone
Study: 28481068
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (EPN) in group A
Study: 28481068
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid therapy in group B
Study: 25633257
Drug: Bone-anchored suspension
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-anchored suspension technique (BAST)
Study: 21811136
Drug: Cobicistat 150
Normalized name: cobicistat 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobicistat 150 mg with atazanavir and emtricitabine/tenofovir df
Study: 21811136
Drug: Ritonavir 100
Normalized name: ritonavir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 100 mg with atazanavir and emtricitabine/tenofovir df
Study: 19726078
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg loading dose) with PPI
Study: 19726078
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg loading dose) without PPI
Study: 19726078
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg loading dose) with PPI
Study: 19726078
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg loading dose) without PPI
Study: 15296999
Drug: Follow-up investigation
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up investigation after optimising therapy in narcolepsy patients
Study: 11255137
Drug: 1.0-g glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0-g glycerol x kg body weight(-1) + 30% of the total rehydration water volume (GLY)
Study: 9249117
Drug: Epidural meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural meperidine 25 mg diluted with saline to 2 mL (12.5 mg/mL)
Study: 9249117
Drug: Epidural meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural meperidine 25 mg diluted with saline to 5 mL (5 mg/mL)
Study: 9249117
Drug: Epidural meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural meperidine 25 mg diluted with saline to 10 mL (2.5 mg/mL)
Study: 8074624
Drug: Phenytoin 200
Normalized name: phenytoin 200 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 200 mg
Study: 31790543
Drug: Fenfluramine, 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine, 0.4 mg/kg/d (maximum, 17 mg/d)
Study: 24942766
Drug: Olmesartan/Amlodipine 10/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/Amlodipine 10/5 mg
Study: 24942766
Drug: Olmesartan/Amlodipine 20/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/Amlodipine 20/5 mg
Study: 24942766
Drug: Olmesartan/Amlodipine 40/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/Amlodipine 40/5 mg
Study: 24942766
Drug: Olmesartan/Amlodipine 40/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/Amlodipine 40/10 mg
Study: 18294111
Drug: Once-daily abacavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily abacavir 600 mg-lamivudine 300 mg
Study: 18294111
Drug: Twice-daily abacavir
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily abacavir 300 mg and lamivudine 150 mg
Study: 15307433
Drug: Sulfadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (SP) alone (1.25 mg/kg based on pyrimethamine)
Study: 15307433
Drug: Artesunate plus
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate plus SP (1 dose: 4 mg/kg/d for 1 day)
Study: 15307433
Drug: Artesunate plus
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate plus SP (3 doses: 4 mg/kg/d for 3 days)
Study: 10884466
Drug: Transcranial Doppler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Doppler ultrasound with Valsalva maneuver (VM) for 5 seconds starting 5 seconds after the beginning of contrast injection
Study: 10884466
Drug: Transcranial Doppler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Doppler ultrasound with VM for 5 seconds starting 2 seconds after the beginning of contrast injection
Study: 10884466
Drug: Transcranial Doppler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Doppler ultrasound with VM for 5 seconds starting 8 seconds after the beginning of contrast injection
Study: 10884466
Drug: Transcranial Doppler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Doppler ultrasound with repetitive short VMs in between 2 and 13 seconds after the beginning of contrast injection
Study: 3549705
Drug: Phenelzine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine 75 mg
Study: 12707430
Drug: Imipramine 150
Normalized name: imipramine pamoate 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 150 mg
Study: 31728715
Drug: Intermittent 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent 5 doses of filgrastim (5 mcg/kg/day)
Study: 31728715
Drug: Once-a-cycle pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once-a-cycle pegfilgrastim (6 mg)
Study: 22741253
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (electroacupuncture + Dalitong granule)
Study: 31998163
Drug: Recreational Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational Therapy (RT)
Study: 15662532
Drug: Storage in
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Storage in lactic acid solution for 3 days
Study: 12869081
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 750 mg of intravenous cefuroxime
Study: 12869081
Drug: Patients already
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients already receiving antibiotics for prior indications
Study: 9477785
Drug: Hydroxyapatite-coated implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyapatite-coated implants
Study: 10531745
Drug: Non-coated commercially
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-coated commercially pure titanium implants
Study: 10159954
Drug: Passive hyperimmune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive hyperimmune therapy
Study: 8495871
Drug: Postoperative start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative start of thromboprophylaxis with low molecular weight heparin
Study: 3086899
Drug: Isosorbide 5-mononitrate
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide 5-mononitrate 40 mg twice daily
Study: 3086899
Drug: Sustained-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release isosorbide dinitrate 40 mg twice daily
Study: 29485019
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed hand hygiene (DOHH) performed at two-hourly intervals during daytime, before meals and medication rounds by a trained nurse.
Study: 22180390
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality cognitive-behavior therapy (VRCBT)
Study: 20143246
Drug: Topiramate 25
Normalized name: topiramate 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 25 mg/day
Study: 18677327
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (part of a 4-year randomized controlled trial)
Study: 8683230
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 40 mg four times daily
Study: 1874767
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of cefonicid (Group I)
Study: 1874767
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of cefamandole (Group II)
Study: 1874767
Drug: Five doses
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five doses of cefamandole (Group III)
Study: 7097431
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with imipramine hydrochloride
Study: 19545211
Drug: Vaccine dose
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine dose of 1 X 10(4) ffu
Study: 19545211
Drug: Vaccine dose
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine dose of 1 X 10(5) ffu
Study: 15302293
Drug: metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 850 mg two times per day
Study: 15302293
Drug: lifestyle modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: lifestyle modification plus metformin 850 mg two times per day
Study: 9643401
Drug: Routine adoption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine adoption of HIV infection control guidelines during delivery (including protective glasses, impermeable garments, mask, sterile latex gloves, washing hands with detergent solution after using gloves, and collecting needles in suitable containers)
Study: 8036463
Drug: Topical metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical metronidazole treatment (40-160 mg daily)
Study: 25925729
Drug: Topical metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical metronidazole treatment
Study: 31092443
Drug: S-1 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (80 mg/m2) plus cisplatin (80 mg/m2) with bevacizumab (15 mg/kg) followed by maintenance with bevacizumab plus S-1 (SCB)
Study: 31092443
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) with bevacizumab (15 mg/kg) followed by maintenance with bevacizumab plus pemetrexed (PCB)
Study: 21777229
Drug: Prednisolone (40-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40-60 mg/day for 2 weeks)
Study: 9191638
Drug: Low-angle cases
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-angle cases (ML/NSL < 25 degrees)
Study: 3930309
Drug: Miraxid (pivmecillinam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miraxid (pivmecillinam 200 mg plus pivampicillin 250 mg)
Study: 3533674
Drug: Augmentin (amoxycillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentin (amoxycillin 250 mg plus clavulanic acid 125 mg)
Study: 31620856
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 30 ml 0.25% bupivacaine
Study: 27472452
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) for SPOV, 12 sessions
Study: 22516357
Drug: Intravesical 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical 2% chondroitin sulfate (20 mL, 8 weekly instillations)
Study: 22516357
Drug: Inactive control
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive control solution (20 mL, 8 weekly instillations)
Study: 22516357
Drug: Inactive control
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive control solution
Study: 12517682
Drug: perindopril 8
Normalized name: perindopril 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindopril 8 mg
Study: 12939564
Drug: felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine 10 mg
Study: 12517682
Drug: hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrochlorothiazide 50 mg
Study: 9038465
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate 10 mg orally pre-operatively
Study: 6487753
Drug: Controlled-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release formulation of sodium salicylate (NaSA)
Study: 6487753
Drug: Enteric-coated tablet
Normalized name: Walgreens Low Dose Aspirin 81mg Enteric-Coated Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated tablet of sodium salicylate (NaSA)
Study: 6487753
Drug: Solution of
Normalized name: Solution of protein-free hemodialysate of calf blood
DrugBank: SM-1997 (DB18670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution of sodium salicylate (NaSA)
Study: 29288141
Drug: Increased number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased number of medications
Study: 22302127
Drug: Oral almorexant
Normalized name: Nemorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral almorexant 200 mg
Study: 22302127
Drug: Intravenous almorexant
Normalized name: Nemorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous almorexant 20 mg
Study: 20571832
Drug: Bupivacaine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (200 mg) with 0.5 mg epinephrine
Study: 20571832
Drug: Levobupivacaine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (200 mg) with 0.5 mg epinephrine
Study: 16043829
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/d combined with carboplatin and paclitaxel
Study: 9785782
Drug: Saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group (n = 15) - received saline 10 ml injected through an epidural catheter 20 min after spinal anesthesia
Study: 9785782
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 15) - received 2% lidocaine 3 ml with 0.4% tetracaine injected into the subarachnoid space; saline was not injected into the epidural space
Study: 8585716
Drug: Adefovir 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir 1.0 mg/kg intravenous infusion
Study: 8585716
Drug: Adefovir 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir 3.0 mg/kg intravenous infusion
Study: 8585716
Drug: Adefovir 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir 1.0 mg/kg/day for 22 days
Study: 8585716
Drug: Adefovir 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir 3.0 mg/kg/day for 22 days
Study: 8585716
Drug: Adefovir 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir 3.0 mg/kg oral dose
Study: 8585716
Drug: Adefovir 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir 3.0 mg/kg subcutaneous dose
Study: 31186150
Drug: ARA‐25 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARA‐25 (25 g ARA/100 kcal, no added prebiotic blend)
Study: 31186150
Drug: PDX/GOS (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDX/GOS (34 mg ARA/100 kcal, with prebiotic blend)
Study: 31186150
Drug: Control (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (34 mg ARA/100 kcal, no added prebiotic blend)
Study: 16681586
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% 5-FU ointment
Study: 16681586
Drug: Placebo aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo aqueous cream
Study: 14713798
Drug: 15 cc
Normalized name: OCTINOXATE 50 mg in 1 mL TOPICAL CREAM [flormar CC Magical Color Effect Color Correcting Cream Sunscreen Broad Spectrum SPF 15 CC02]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 cc 2% lidocaine gel administered intrarectally 10 minutes before biopsy
Study: 14713798
Drug: 10 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc 1% lidocaine under ultrasound guidance as 2 periprostatic injections of 5 cc 5 minutes prior to biopsy
Study: 9863105
Drug: Ligustrazine (LGT)
Normalized name: ligustrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligustrazine (LGT) administered by intravenous drip before occlusion and immediately after release
Study: 3294815
Drug: trifluoperazine 1
Normalized name: trifluoperazine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: trifluoperazine 1 mg b.i.d.
Study: 3294815
Drug: haloperidol 0.5
Normalized name: haloperidol 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol 0.5 mg b.i.d.
Study: 19224089
Drug: Melatonin (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (9 mg sublingually)
Study: 15117042
Drug: saline (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline (control group) and midazolam 7.5 mg given orally 30‐60 minutes before induction
Study: 11281386
Drug: G-CSF-mobilized peripheral
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF-mobilized peripheral blood stem cell transplantation (BCT)
Study: 7951550
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy with insulin and fluid administration
Study: 27241991
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish treatment once a month for 6 months
Study: 27241991
Drug: Fluoride film
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride film treatment once a month for 6 months
Study: 24239143
Drug: Patient Benefit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Benefit Index (PBI-L)
Study: 8282334
Drug: cilazapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril (2.5 to 5 mg/d)
Study: 17386354
Drug: atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (50 to 100 mg/d)
Study: 2643672
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine chewing gum
Study: 3585679
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nicotine chewing gum
Study: 28917657
Drug: ATRA plus
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA plus danazol (10 mg twice daily + 200 mg twice daily)
Study: 7577849
Drug: Danazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (200 mg twice daily)